JP2018059791A - 赤血球の凝集方法及び分離方法並びに赤血球凝集用試薬 - Google Patents
赤血球の凝集方法及び分離方法並びに赤血球凝集用試薬 Download PDFInfo
- Publication number
- JP2018059791A JP2018059791A JP2016196963A JP2016196963A JP2018059791A JP 2018059791 A JP2018059791 A JP 2018059791A JP 2016196963 A JP2016196963 A JP 2016196963A JP 2016196963 A JP2016196963 A JP 2016196963A JP 2018059791 A JP2018059791 A JP 2018059791A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- reagent
- erythrocytes
- red blood
- hemagglutination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 91
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 34
- 230000035931 haemagglutination Effects 0.000 title claims abstract description 23
- 238000000926 separation method Methods 0.000 title abstract description 17
- 230000004520 agglutination Effects 0.000 title abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 47
- 239000008280 blood Substances 0.000 claims abstract description 47
- 239000004094 surface-active agent Substances 0.000 claims abstract description 44
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims abstract description 42
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims abstract description 42
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000004380 Cholic acid Substances 0.000 claims abstract description 40
- 235000019416 cholic acid Nutrition 0.000 claims abstract description 40
- 229960002471 cholic acid Drugs 0.000 claims abstract description 40
- 239000002253 acid Substances 0.000 claims abstract description 33
- 230000004523 agglutinating effect Effects 0.000 claims abstract description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 229940045946 sodium taurodeoxycholate Drugs 0.000 claims description 5
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical group [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 claims description 5
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 claims description 4
- 238000003320 cell separation method Methods 0.000 abstract description 2
- 230000002776 aggregation Effects 0.000 description 34
- 238000004220 aggregation Methods 0.000 description 33
- 239000000523 sample Substances 0.000 description 33
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 12
- 206010018910 Haemolysis Diseases 0.000 description 11
- 230000008588 hemolysis Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010876 biochemical test Methods 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- -1 deoxycholic acid Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000004931 aggregating effect Effects 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- ZFGOPJASRDDARH-UHFFFAOYSA-N 3-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C(C2)C1(C)CCC2OC1CC2=CCC3C4CCC(C(C)CCCC(C)C)C4(C)CCC3C2(C)CC1 ZFGOPJASRDDARH-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- XBSQTYHEGZTYJE-OETIFKLTSA-N glycolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 XBSQTYHEGZTYJE-OETIFKLTSA-N 0.000 description 2
- 239000003219 hemolytic agent Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010049190 Red blood cell agglutination Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000002812 cholic acid derivative Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4044—Concentrating samples by chemical techniques; Digestion; Chemical decomposition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5002—Partitioning blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
本発明において、血液試料とは、ヒト又は動物の被検者から採血により取得した、赤血球が含まれる試料である。血液試料としては、被検者から採血した全血をそのまま使用してもよく、採取した全血を生理食塩水等で希釈した試料を用いてもよいが、操作の簡便性の点から、被検者から採血した全血をそのまま使用するのが好ましい。本発明の方法において使用する血液試料の量は、通常10μl〜50mlであり、望ましくは10μl〜1mlであり、より望ましくは10μl〜100μlである。
本発明で使用するコール酸系界面活性剤とは、分子内にステロイド骨格を有する界面活性剤であり、具体的にはコール酸又はコール酸の誘導体の構造を有する界面活性剤である。ここで、コール酸誘導体とは、コール酸から誘導されるあらゆる化合物を意味するが、具体的には、デオキシコール酸等の脱ヒドロキシル基化合物、タウロデオキシコール酸等の置換アミド化合物等が挙げられる。
本発明で使用する酸としては、水溶液中で水素イオン(H+)を出す物質であればよい。具体的には、無機酸及び有機酸並びにそれらの塩が挙げられる。無機酸としては、塩酸、臭化水素酸、硫酸、スルファミン酸、リン酸、硝酸等が挙げられる。有機酸としては、例えば酢酸、プロピオン酸、コハク酸、グリコール酸、ステアリン酸、乳酸、リンゴ酸、酒石酸、クエン酸、マロン酸、アスコルビン酸、パモン酸、マレイン酸、アジピン酸、アルギン酸、アスパラギン酸、ヒドロキシマレイン酸、フェニル酢酸、グルタミン酸、安息香酸、サリチル酸、スルファニル酸、2−アセトキシ安息香酸、フマル酸、ベンゼンスルホン酸、トルエンスルホン酸、メタンスルホン酸、2−ナフタレンスルホン酸、エタンジスルホン酸、シュウ酸、イセチオン酸、グルコヘプタン酸、グリセロリン塩、ヘミスルファニックアシッド(hemisulfanic acid)、ヘプタン酸、ヘキサン酸、塩酸、臭化水素酸、ヨウ化水素酸、2−ヒドロキシエタンスルホン酸、2−ナフタレンスルホン酸、ペクチニン酸、リン酸、硫酸、3−フェニルプロピオン酸、ピクリン酸、ピバル酸、チオシアン酸、p−トルエンスルホン酸、酪酸、カンフル酸、ショウノウスルホン酸、ジグルコン酸、シクロペンタンプロピオン酸、双硫酸、ドデシル硫酸、エタンスルホン酸、及びウンデカン酸等が挙げられる。本発明において酸は、単独で用いてもよく、2種類以上を組み合わせて用いてもよい。
本発明においては、血液試料に、前記コール酸系界面活性剤及び酸を含む溶液を添加することにより、赤血球を凝集させる。血液試料に添加する、このようなコール酸系界面活性剤及び酸を含む溶液は、赤血球を凝集させるための試薬(赤血球凝集用試薬)として用いることが出来る。
赤血球凝集試薬中のコール酸系界面活性剤と酸との比率(モル比)は、凝集速度と赤血球のより完全な分離の観点から、通常1:7〜1:2000であり、1:8〜1:1667が望ましく、1:13〜1:1333がより望ましく、1:17〜1:1000が特に望ましい。使用する血液試料に対する赤血球凝集試薬の添加量(体積比)は、通常1:4〜1:80好ましくは1:8〜1:20、より好ましくは1:10〜1:13である。
本発明においては、血液試料に上記赤血球凝集試薬を室温でそのまま添加すれば、赤血球が十分な大きさに瞬時に凝集するが、凝集をより完全に進行させるためには、血液試料を赤血球凝集試薬と接触させた状態で、5秒〜30秒、望ましくは5秒程度静置後、数回転倒混和するのがよい。このようにして赤血球を凝集させることにより、十分な大きさを有する凝集物を得ることが出来る。
コール酸系界面活性剤及び塩の有無とpH範囲による赤血球凝集
++:赤血球が数秒静置後に凝集しはじめ、次第に赤血球の凝集物が沈殿した
+:赤血球の凝集は起こったが、凝集物は微小であり凝集が不完全であった
±:赤血球の凝集はごく僅かであった
−:凝集せずに溶血した
結果を下記表1に示す。
なお、赤血球凝集用試薬のpHは、HORIBA 卓上型pHメーターを用いて測定した(以下の実施例及び比較例において同様である)。
生理食塩水に各種コール酸系界面活性剤(1重量%)とクエン酸(100mM)を添加して赤血球凝集用試薬(pH3.0)を調製し、赤血球の凝集能を比較した。
赤血球凝集用試薬400μLに全血検体60μLを添加して、赤血球の凝集速度を確認した。凝集速度は以下に記載した基準に基づき、速い順に+++>++>+>±とし、凝集せずに溶血した場合は−とした。なお、以下の基準は、上記実施例1〜4、及び比較例1−1〜4−2の基準と同一である。
++:赤血球が数秒静置後に凝集しはじめ、次第に赤血球の凝集物が沈殿した
+:赤血球の凝集は起こったが、凝集物は微小であり凝集が不完全であった
±:赤血球の凝集はごく僅かであった
−:凝集せずに溶血した
結果を下記表2に示す。
生理食塩水にタウロデオキシコール酸ナトリウム水和物(TDOC)とクエン酸(100mM)を添加して赤血球凝集用試薬(pH3.0)を調製し、下記表に示すTDOCの濃度範囲について赤血球の凝集能を比較した。
++:赤血球が数秒静置後に凝集しはじめ、次第に赤血球の凝集物が沈殿した
+:赤血球の凝集は起こったが、凝集物は微小であり凝集が不完全であった
±:赤血球の凝集はごく僅かであった
−:凝集せずに溶血した
結果を下記表3に示す。
また、上記実施例1〜4において赤血球の凝集物が沈殿した後の上清を分離し、この分離した上清をイムノクロマトキット(QuickNavi(登録商標)−Ebola)に滴下して、メンブレン上の移動を観察したところ、メンブレンは赤色に着色しなかった。この結果からも、上記分離後の上清は実質的に赤血球を含まず、生化学検査用の分析用試料として好適であることが裏付けられた。
Claims (7)
- 血液試料に、コール酸系界面活性剤及び酸を含有する溶液を添加することを含む、赤血球の凝集方法。
- 前記溶液のpHが、2.5〜4.0である請求項1記載の方法。
- 前記コール酸系界面活性剤が、タウロデオキシコール酸ナトリウム水和物である請求項1又は2記載の方法。
- 請求項1〜3のいずれか一項記載の方法により凝集させた赤血球を分離することを含む、血液試料からの赤血球の分離方法。
- コール酸系界面活性剤及び酸を含有する赤血球凝集用試薬。
- 前記試薬のpHが、2.5〜4.0である請求項5記載の試薬。
- 前記コール酸系界面活性剤が、タウロデオキシコール酸ナトリウム水和物である請求項5又は6記載の試薬。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016196963A JP6889535B2 (ja) | 2016-10-05 | 2016-10-05 | 赤血球の凝集方法及び分離方法並びに赤血球凝集用試薬 |
EP17858425.6A EP3524978B1 (en) | 2016-10-05 | 2017-10-04 | Method for agglutinating erythrocytes, method for separating erythrocytes, and hemagglutination reagent |
PCT/JP2017/036087 WO2018066588A1 (ja) | 2016-10-05 | 2017-10-04 | 赤血球の凝集方法及び分離方法並びに赤血球凝集用試薬 |
MYPI2019001660A MY197112A (en) | 2016-10-05 | 2017-10-04 | Method for agglutinating erythrocytes, method for separating erythrocytes, and hemagglutination reagent |
ES17858425T ES2895133T3 (es) | 2016-10-05 | 2017-10-04 | Método para aglutinar eritrocitos, método para separar eritrocitos y reactivo de hemaglutinación |
CN201780061966.8A CN110073211B (zh) | 2016-10-05 | 2017-10-04 | 红细胞的凝集方法和分离方法以及红细胞凝集用试剂 |
KR1020197011801A KR102363109B1 (ko) | 2016-10-05 | 2017-10-04 | 적혈구의 응집 방법 및 분리 방법, 및 적혈구 응집용 시약 |
US16/339,655 US11320350B2 (en) | 2016-10-05 | 2017-10-04 | Method for agglutinating erythrocytes, method for separating erythrocytes, and hemagglutination reagent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016196963A JP6889535B2 (ja) | 2016-10-05 | 2016-10-05 | 赤血球の凝集方法及び分離方法並びに赤血球凝集用試薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018059791A true JP2018059791A (ja) | 2018-04-12 |
JP6889535B2 JP6889535B2 (ja) | 2021-06-18 |
Family
ID=61832155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016196963A Active JP6889535B2 (ja) | 2016-10-05 | 2016-10-05 | 赤血球の凝集方法及び分離方法並びに赤血球凝集用試薬 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11320350B2 (ja) |
EP (1) | EP3524978B1 (ja) |
JP (1) | JP6889535B2 (ja) |
KR (1) | KR102363109B1 (ja) |
CN (1) | CN110073211B (ja) |
ES (1) | ES2895133T3 (ja) |
MY (1) | MY197112A (ja) |
WO (1) | WO2018066588A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021182575A1 (ja) * | 2020-03-11 | 2021-09-16 | 積水メディカル株式会社 | 白血球濃縮分離デバイス、血液採取容器及び白血球の分離方法 |
WO2023048112A1 (ja) | 2021-09-21 | 2023-03-30 | 日東紡績株式会社 | 分析用血球分離剤及び血球分離方法 |
WO2023048115A1 (ja) | 2021-09-21 | 2023-03-30 | 日東紡績株式会社 | 血球分離剤、およびそれを用いた血球分離方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111568938B (zh) * | 2020-03-02 | 2023-09-08 | 九江学院 | 有机酸在促进旱莲草提取物止凝血活性中的应用 |
KR20240019074A (ko) * | 2021-06-07 | 2024-02-14 | 덴카 주식회사 | 분변 검체의 검사 방법 및 그것을 위한 이뮤노크로마토그래피 시험편 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307087A1 (en) * | 1987-08-05 | 1989-03-15 | Alliance Pharmaceutical Corp. | Fluorocarbon emulsions for in vivo use |
JPH06507475A (ja) * | 1990-11-09 | 1994-08-25 | アボット・ラボラトリーズ | 希釈緩衝液およびその使用法 |
JP2005114359A (ja) * | 2003-10-02 | 2005-04-28 | Matsushita Electric Ind Co Ltd | 血液中のグルコースの測定方法およびそれに用いるセンサ |
WO2006109685A1 (ja) * | 2005-04-06 | 2006-10-19 | Nippon Kayaku Kabushiki Kaisha | 血漿または血清の採取方法 |
WO2013147307A1 (ja) * | 2012-03-30 | 2013-10-03 | 積水メディカル株式会社 | 赤血球含有サンプル中の対象物を検出するためのイムノクロマトグラフィー用テストストリップおよびイムノクロマトグラフィーを利用した検出方法 |
US20150204843A1 (en) * | 2012-08-30 | 2015-07-23 | Qiagen Gmbh | Method for obtaining blood plasma from a whole blood sample |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4299726A (en) | 1979-05-07 | 1981-11-10 | Coulter Electronics, Inc. | Process for preparing whole blood reference controls having long term stability, preconditioning diluent and media therefor |
JPH0726960B2 (ja) * | 1988-04-05 | 1995-03-29 | 富士写真フイルム株式会社 | 乾式全血分析要素 |
US5118428A (en) | 1990-11-13 | 1992-06-02 | Quidel | Method to remove red blood cells from whole blood samples |
JPH05172816A (ja) * | 1991-05-13 | 1993-07-13 | Denka Seiken Co Ltd | 抗原の測定方法 |
ATE193603T1 (de) | 1992-02-24 | 2000-06-15 | Coulter Corp | Suspensionsmedien für hämatoligische zusammensetzungen und methode für ihren gebrauch |
US5981294A (en) | 1995-11-29 | 1999-11-09 | Metrika, Inc. | Device for blood separation in a diagnostic device |
US6033866A (en) * | 1997-12-08 | 2000-03-07 | Biomedix, Inc. | Highly sensitive amperometric bi-mediator-based glucose biosensor |
CN1243251A (zh) * | 1998-07-28 | 2000-02-02 | 华美生物工程公司郑州分公司 | 全血免疫检测试剂中红细胞和血清的分离方法 |
US8580532B2 (en) * | 2006-12-21 | 2013-11-12 | Sekisui Medical Co., Ltd. | Method for stabilizing α-thrombin in thrombin-containing solution |
JP6036212B2 (ja) | 2012-11-20 | 2016-11-30 | ニプロ株式会社 | ヘモグロビン測定装置およびヘモグロビン測定方法 |
-
2016
- 2016-10-05 JP JP2016196963A patent/JP6889535B2/ja active Active
-
2017
- 2017-10-04 KR KR1020197011801A patent/KR102363109B1/ko active IP Right Grant
- 2017-10-04 WO PCT/JP2017/036087 patent/WO2018066588A1/ja unknown
- 2017-10-04 CN CN201780061966.8A patent/CN110073211B/zh active Active
- 2017-10-04 MY MYPI2019001660A patent/MY197112A/en unknown
- 2017-10-04 US US16/339,655 patent/US11320350B2/en active Active
- 2017-10-04 EP EP17858425.6A patent/EP3524978B1/en active Active
- 2017-10-04 ES ES17858425T patent/ES2895133T3/es active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307087A1 (en) * | 1987-08-05 | 1989-03-15 | Alliance Pharmaceutical Corp. | Fluorocarbon emulsions for in vivo use |
JPH06507475A (ja) * | 1990-11-09 | 1994-08-25 | アボット・ラボラトリーズ | 希釈緩衝液およびその使用法 |
JP2005114359A (ja) * | 2003-10-02 | 2005-04-28 | Matsushita Electric Ind Co Ltd | 血液中のグルコースの測定方法およびそれに用いるセンサ |
WO2006109685A1 (ja) * | 2005-04-06 | 2006-10-19 | Nippon Kayaku Kabushiki Kaisha | 血漿または血清の採取方法 |
WO2013147307A1 (ja) * | 2012-03-30 | 2013-10-03 | 積水メディカル株式会社 | 赤血球含有サンプル中の対象物を検出するためのイムノクロマトグラフィー用テストストリップおよびイムノクロマトグラフィーを利用した検出方法 |
US20150204843A1 (en) * | 2012-08-30 | 2015-07-23 | Qiagen Gmbh | Method for obtaining blood plasma from a whole blood sample |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021182575A1 (ja) * | 2020-03-11 | 2021-09-16 | 積水メディカル株式会社 | 白血球濃縮分離デバイス、血液採取容器及び白血球の分離方法 |
WO2023048112A1 (ja) | 2021-09-21 | 2023-03-30 | 日東紡績株式会社 | 分析用血球分離剤及び血球分離方法 |
WO2023048115A1 (ja) | 2021-09-21 | 2023-03-30 | 日東紡績株式会社 | 血球分離剤、およびそれを用いた血球分離方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6889535B2 (ja) | 2021-06-18 |
EP3524978B1 (en) | 2021-09-22 |
US11320350B2 (en) | 2022-05-03 |
US20190226952A1 (en) | 2019-07-25 |
KR102363109B1 (ko) | 2022-02-15 |
EP3524978A4 (en) | 2020-06-17 |
WO2018066588A1 (ja) | 2018-04-12 |
KR20190065320A (ko) | 2019-06-11 |
CN110073211B (zh) | 2021-06-08 |
EP3524978A1 (en) | 2019-08-14 |
CN110073211A (zh) | 2019-07-30 |
MY197112A (en) | 2023-05-26 |
ES2895133T3 (es) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018066588A1 (ja) | 赤血球の凝集方法及び分離方法並びに赤血球凝集用試薬 | |
Arain et al. | A new dispersive liquid–liquid microextraction using ionic liquid based microemulsion coupled with cloud point extraction for determination of copper in serum and water samples | |
Ononogbu et al. | Lipoprotein fractionation by a precipitation method. A simple quantitative procedure | |
Larcom et al. | Erythrocytes in urinary sediment: Identification and normal limits: With a note on the nature of granular casts | |
Smolen et al. | Permeability changes induced by peroxidation in liposomes prepared from human erythrocyte lipids | |
TW201348707A (zh) | 一種輸血前配合試驗之試劑組及其試驗方法 | |
CN102834719B (zh) | 回避内源性脂蛋白的影响的方法及试剂 | |
Smith et al. | Cellular lipoproteins: I. The insoluble lipoprotein of whole liver cells | |
JP2001503863A (ja) | タンパク質の抽出方法 | |
Man et al. | Permeability of capillaries to plasma lipoids | |
Ismail et al. | Testosterone assays: guidelines for the provision of a clinical biochemistry service | |
RU2530627C2 (ru) | Экспресс-способ определения холестерина в иммунных комплексах | |
DE3118072A1 (de) | Verfahren zur trennung von lipophilen bestandteilen aus waessrigen kolloid-loesungen zu praeparativen zwecken und/oder zum nachweis eines analyts in waessriger phase | |
JPWO2004106930A1 (ja) | イムノクロマトグラフ法 | |
Hussein | Effect of cigarettes smoking on the serum levels of calcium and phosphate in Sudanese males in Khartoum | |
Kahn | The Kahn precipitation test for syphilis | |
Schurtenberger et al. | Dynamic Micelle Laser Light Scattering Studies of the to Vesicle Transition in Model and Native Bile | |
JP5963984B2 (ja) | 甲状腺刺激抗体測定における試料の前処理方法 | |
US20220163520A1 (en) | Apparatus, method and kit for detection of von willebrand factor and factor viii | |
EP1664771A2 (en) | A method for qualitative and/or quantitative detection of polyethylene glycols in biological fluids | |
Talafant et al. | Turbidimetric determination of lipoprotein-X in serum | |
JP2004109034A (ja) | 抗リン脂質抗体の検査方法及び試薬 | |
RU2353930C2 (ru) | СПОСОБ ЭКСПРЕСС-ОПРЕДЕЛЕНИЯ b-ЛИПОПРОТЕИДОВ В СЫВОРОТКЕ КРОВИ | |
RU2190852C2 (ru) | Способ оценки функции коры надпочечников | |
Castro et al. | Evaluation of oral fluid specimens for syphilis testing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190910 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20200609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201028 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201211 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210426 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210521 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6889535 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |